ArticleEuropean heart journal open2026
Ablation of visually identified spatiotemporal dispersion plus pulmonary vein isolation in persistent atrial fibrillation.
Article in European heart journal open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: Pulmonary vein isolation (PVI) provides limited efficacy in persistent atrial fibrillation (AF). We performed PVI plus ablation of areas with visually detected spatiotemporal dispersion (STD) in consecutive patients with persistent AF, and compared them with a 1:1 propensity score-matched cohort of patients treated with a PVI-only approach. Methods and results: STD was visually identified using conventional high-density mapping catheters (IntellaMap ORION, PentaRay NAV, or Advisor HD Grid), without dedicated software. Areas with STD showing fractionated continuous electrograms (FCEs), if present, were ablated first, and other areas with STD were ablated in cases without AF conversion during ablation of FCEs. The right atrium was treated only in cases without AF conversion during left atrial ablation in which the AF cycle length was faster at the right atrium. Hundred patients were treated with each ablation strategy (PVI + STD or PVI-only) (63.9 ± 10.1 years, 28% females). Thirty-five patients from the PVI + STD group showed areas with FCEs, which were ablated first, achieving AF termination in nine patients. In the remaining 91 patients, 221 areas with STD were ablated. The right atrium was treated in 48 patients. Globally, AF conversion was achieved in 33 patients. The PVI + STD group showed lower atrial arrhythmia recurrences at 18-month follow-up (30% vs. 53%, Conclusion: Ablation of areas with visually identified STD, added to PVI, reduced atrial arrhythmia recurrences and decreased progression to permanent AF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.